CD274 and non-small cell lung carcinoma: Nowadays, treatments with PD-L1 and PD-1 blockers, intended to induce anti-tumor lymphocytes, fail in 80% of NSCLC patients (Borghaei et al., 2015; Horn et al., 2017).